Plasminogen activator inhibitor-1: A review

LaboratoriumsMedizin

Volumn 29, Issue 6, 2005, Pages 403-411

  Pihusch, Markus ^a   Pihusch, Verena ^b   Holler, Ernst ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Cancer; Fibrinolysis; Fibrosis; Inflammation; Insulin resistance; Plasminogen activator inhibitor 1; Pregnancy

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA1; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADIPOCYTE; ANOVULATION; BLOOD CLOT LYSIS; CANCER INVASION; CELL MIGRATION; EXTRACELLULAR MATRIX; FIBRINOLYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; HISTOPATHOLOGY; HUMAN; LIVER CELL; MATERNAL HYPERTENSION; METABOLIC DISORDER; NON INVASIVE MEASUREMENT; NON INVASIVE PROCEDURE; OVARY POLYCYSTIC DISEASE; PREECLAMPSIA; PREGNANCY COMPLICATION; PROGNOSIS; PROTEIN DEGRADATION; REVIEW; SMOOTH MUSCLE FIBER; SPONTANEOUS ABORTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTE ACTIVATION; UPREGULATION; VASCULAR FIBROSIS;

EID: 29344453402     PISSN: 03423026     EISSN: 14390477     Source Type: Journal    
DOI: 10.1515/JLM.2005.055     Document Type: Review

References (98)

1. Loskutoff DJ. A slice of PAI. J Clin Invest 1993;92:2563.
2. Kruithof EKO. Plasminogen activator inhibitors - a review. Enzyme 1988;40:13-121.
3. Brakman P, Astrup T. Selective inhibition in human pregnancy blood of urokinase induced fibrinolysis. Scand J Clin Lab Invest 1963;15:603.
4. Lecander I, Åstedt B. Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma. Br J Haemat 1986;62:221-8.
5. Stump DC, Thienpont M, Collen D. Purification and characterization of a novel inhibitor of urokinase from human urine. J Biol Chem 1986;261:12759-66.
6. Scott RW, Bergman BL, Bajpai A, Hersh RT, Rodriguez H, Jones BN, et al. Protease nexin. Properties and a modified purification procedure. J Biol Chem 1985;260:7029-34.
7. Dellas C, Loskutoff DJ. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 2005;93:631-40.
8. Binder BR, Christ G, Gruber F, Grubic N, Hufnagl P, Krebs M, et al. Plasmin activator inhibitor 1: physiological and pathophysiological roles. News Physiol Sci 2002;17:56-61.
9. Follo M, Ginsburg D. Structure and expression of the human gene encoding plasminogen activator inhibitor, PAI-1. Gene 1989;84:447-53.
10. Lawrence DA, Strandberg L, Ericson J, Ny T. Structure-function studies of the SERPIN plasminogen activator inhibitor type I. J Biol Chem 1990;265:20293-301.
11. Travis J, Salvesen GS. Human plasma proteinase inhibitors. Annu Rev Biochem 1983;52:655.
12. Krishnamurti C, Alving BM. Plasminogen activator inhibitor type 1: Biochemistry and evidence for modulation of fibrinolysis in vivo. Sem Thromb Hem 1992;1:67-80.
13. Kluft C, Verhejen JH, Rijken DC, Chang GT, Jie AFH, Onelinxy C. Diurnal fluctuations in the activity of the fast-acting t-PA inhibitor. In: Davdison JF, Donati MB, Coccheri S, editors. Progress in Fibrinolysis VoI VIII. Edinburgh (Great Britain): Churchill Livingstone 1985:117.
14. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987;69:381-7.
15. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. Direct binding of Smad 3 and Smad 4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 1998;17:3091-100.
16. Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J. PPAR-gamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPAR-gamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 1999;19:546-51.
17. Kunz C, Pebler S, Otte J, von der Ahe D. Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. Nucleic Acids Res 1995;23:3710-7.
18. Nykjaer A, Conese M, Christensen EI, Olson D, Cremona O, Gliemann J, et al. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J 1997;16:2610-20.
19. Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost 2003;29:125-30.
20. Sie P, Caron C, Azam J, Goudemand J, Grandjean H, Boneu B, et al. Reassessment of von Willebrand factor (VWF), VWF propeptide, factor VIII:C and plasminogen activator inhibitors 1 and 2 during normal pregnancy. Br J Haematol 2003;121:897-903.
21. Sartori MT, Wiman B, Vettore S, Dazzi F, Girolami A, Patrassi GM. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis. Thromb Haemost 1998;80:956-60.
22. Glueck CJ, Wang P, Goldenberg N, Sieve L. Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin. Clin Appl Thromb Hemost 2004;10:323-34.
23. Buchholz T, Lohse P, Rogenhofer N, Kosian E, Pihusch R, Thaler CJ. Polymorphisms in the ACE and PAI-1 genes are associated with recurrent spontaneous miscarriages. Hum Reprod 2003;18:2473-7.
24. Hefler L, Jirecek S, Heim K, Grimm C, Antensteiner G, Zeillinger R, et al. Genetic polymorphisms associated with thrombophilia and vascular disease in women with unexplained late intrauterine fetal death: a multicenter study. Soc Gynecol Investig 2004;11:42-4.
25. Bick RL, Hoppensteadt D. Recurrent miscarriage syndrome and infertility due to blood coagulation protein/platelet defects: a review and update. Clin Appl Throm Hemost 2005;111:1-13.
26. Tarkun I, Canturk Z, Arslan BC, Turemen E, Tarkun P. The plasminogen activator system in young and lean women with polycystic ovary sydnrome. Endocr J 2004;51:467-72.
27. Hakli T, Romppanen EL, Hiltunen M, Helisami S, Punnonen K, Heinonen S. Plasminogen activator inhibitor-1 polymorphism in women with pre-eclampsia. Genet Test 2003;7:265-8.
28. Tempfer CB, Jirecek S, Riener EK, Zeisler H, Denschlag D, Hefler L, Husslein PW. Polymorphisms of thrombophilic and vasoactive genes and severe preeclampsia: a pilot study. Soc Gynecol Investig 2004;11:227-31.
29. Yamada N, Arinami T, Yamakawa-Kobayashi K, Watanabe H, Sohda S, Hamada H, et al. The 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene is associated with severe preeclampsia. J Hum Genet 2000;45:138-41.
30. Ma S, Bai C, Bian X. Investigation of thrombomodulin and plasminogen activator inhibitor type-1 in pregnancy induced hypertension and its clinical significance. Chin Med Sci J 2001;16:169-71.
31. Liu YX. Regulation of the plasminogen activator system in the ovary. Biol Signals Recept 1999;8:160-77.
32. Floridon C, Nielsen O, Holund B, Sweep F, Sunde L, Thomsen SG, et al. Does plasminogen activator inhibitor-1 (PAI-1) control trophoblast invasion? A study of fetal and maternal tissue in intrauterine, tubal and molar pregnancies. Placenta 2000;21:754-62.
33. Dano K, Behrendt N, Hoyer-Hansen G, Johnsen M, Lund LR, Ploug M, et al. Plasminogen activation and cancer. Thromb Haemost 2005;93:676-81.
34. Czekay RP, Loskutoff DJ. Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment. Exp Biol Med (Maywood) 2004;229:1090-6.
35. Hildenbrand R, Arens N. Protein and mRNA expression of uPAR and PAI-1 in myoepithelial cells of early breast cancer lesions and normal breast tissue. Br J Cancer 2004;91:564-71.
36. Hundsdorfer B, Zeilhofer HF, Block KP, Dettmar P, Schmitt M, Kolk A, et al. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value. J Craniomaxillofac Surg 2005;33:191-6.
37. Maillard C, Jost M, Romer MU, Brunner N, Houard X, Lejeune A, et al. Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner. Neoplasia 2005;7:57-66.
38. Illemann M, Hansen U, Nielsen HJ, Andreasen PA, Hoyer-Hansen G, Lund LR, et al. Leading-edge myofibroblasts in human colon cancer express plasminogen activator inhibitor-1. Am J Clin Pathol 2004;122:256-65.
39. Stabuc B, Markovic J, Bartenjev I, Vrhovec I, Medved U, Kocijancic B. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and 2 in stage I malignant melanoma. Oncol Rep 2003;10:635-9.
40. Brooks TD, Wang SW, Brunner N, Charton PA. XR5967, a novel modulator of plasminogen activator inhibitor-1 activity, suppresses tumor cell invasion and angiogenesis in vitro. Anticancer Drugs 2004;15:37-44.
41. Meo S, Dittadi R, Peloso L, Gion M. The prognostic value of vascular endothelial growth factor, urokinase plasminogen activator and plasminogen activator inhibitor-1 in node-negative breast cancer. Int J Biol Markers 2004;19:282-8.
42. Duffy MJ. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem 2002;48:1194-7.
43. Duffy MJ, Duggan C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem 2004;37:541-8.
44. Hazelbag S, Kenter GG, Gorter A, Fleuren GJ. Prognostic relevance of TGF-beta1 and PAI-1 in cervical cancer. Int J Cancer 2004;112:1020-8.
45. Werle B, Kotzsch M, Lah TT, Kos J, Gabrijelcic-Geiger D, Spiess E, et al. Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator- receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer. Anticancer Res 2004;24:4147-61.
46. Zhang Q, Wu Y, Ann DK, Messadi DV, Tuan TL, Kelly AP, et al. Mechanisms of hypoxic regulation of plasminogen activator inhibitor-1 gene expression in keloid fibroblasts. J Invest Dermatol 2003;121:1005-12.
47. Brown NJ, Vaughan DE, Fogo AB. Aldosterone and PAI-1: implications for renal injury. J Nephrol 2002;15:230-5.
48. Eddy A. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 2002;283:F209-F20.
49. Cho S, Ryu CH, Oh CK. Plasminogen activator inhibitor-1 in the pathogenesis of asthma. Exp Biol Med 2004;229:138-46.
50. Kim KK, Flaherty KR, Long Q, Hattori N, Sisson TH, Colby TV, et al. A plasminogen activator inhibitor-1 promoter polymorphism and idiopathic interstitial pneumonia. Mol Med 2003;9:52-6.
51. Eitzman DT, Westrick RJ, Xu Z, Tyson J, Ginsburg D. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood 2000;96:4212-5.
52. Takeshita K, Hayashi M, Iino S, Kondo T, Inden Y, Iwase M, et al. Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction. Am J Pathol 2004;164:449-56.
53. Yang SF, Hsieh YS, Tsai CH, Chou MY, Chang YC. The upregulation of type 1 plasminogen activator inhibitor in oral submucous fibrosis. Oral Oncol 2003;39:367-72.
54. Higuchi C, Tanihata Y, Nishimura H, Naito T, Sanaka T. Effects of glucose and plasminogen activator inhibitor-1 on collagen metabolism in peritoneum. Ther Apher Dial 2005;9:173-8.
55. Zhang LP, Takahara T, Yata Y, Furui K, Jin B, Kawada N, et al. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells. J Hepatol 1999;31:703-11.
56. Holler E. Cytokines, viruses, and graft-versus-host disease. Curr Opin Hematol 2002;9:479-84.
57. Healy AM, Gelehrter TD. Induction of plasminogen activator inhibitor-1 in HepG2 human hepatoma cells by mediators of the acute phase response. J Biol Chem 1994;269:19095-100.
58. Macfelda K, Weiss TW, Kaun C, Breuss JM, Zorn G, Oberndorfer U, et al. Plasminogen activator inhibitor-1 expression is regulated by the inflammatory mediators interleukin-1 alpha, tumor necrosis factor-alpha, transforming growth factor-beta and oncostatin M in human cardiac myocytes. J Mol Cell Cardiol 202;34:1681-91.
59. Boncela J, Papiewska I, Fijalkowska I, Walkowiak B, Cierniewski CS. Acute phase protein alpha 1-acid glycoprotein interacts with plasminogen activator inhibitor type 1 and stabilizes its inhibitory activity. J Biol Chem 2001;276:35305-11.
60. Leithauser B, Matthias FR, Nicolai U, Voss R. Hemostatic abnormalities and the severity of illness in patients at the onset of clinically defined sepsis. Possible indication of the degree of endothelial cell activation? Intensive Care Med 1996;22:631-6.
61. Boudjeltia KZ, Piagnerelli M, Brohée D, Guillaume M, Vincent PJL, Remacle C, et al. Relationship between CRP and hypofibrinolysis: Is this a possible way to explain the association between CRP and outcome in critically ill patients? Thromb J 2004;2:2-7.
62. Wallberg-Jonsson S, Cvetkovic JT, Sundqvist KG, Lefvert AK, Rantapaa-Dahlqvist S. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol 2002;29:875-82.
63. Buckova D, Izakovicova Holla L, Vacha J. Polymorphism 4G/5G in the plasminogen activator inhibitor-1 (PAI-1) gene is associated with IgE-mediated allergic diseases and asthma in the Czech population. Allergy 2002;57:446-8.
64. Vrij AA, Rijken J, van Wersch JW, Stockbrugger RW. Coagulation and fibrinolysis in inflammatory bowel disease and in giant cell arteritis. Pathophysiol Haemost Thromb 2003;33:75-83.
65. Desreumaux P, Huet G, Zerimech F, Gambiez L, Balduyck M, Baron P, et al. Acute inflammatory intestinal vascular lesions and in situ abnormalities of the plasminogen activation system in Crohn's disease. Eur J Gastroenterol Hepatol 1999;11:1113-9.
66. Ince A, Eroglu A, Tarhan O, Bulbul M. Peritoneal fibrinolytic activity in peritonitis. Am J Surg 2002;183:67-9.
67. Whawell SA, Wang Y, Fleming KA, Thompson EM, Thompson JN. Localization of plasminogen activator inhibitor-1 production in inflamed appendix by in situ mRNA hybridization. J Pathol 1993;169:67-71.
68. Renckens R, Roelofs JJ, de Waard V, Florquin S, Lijnen HR, Carmeliet P, et al. The role of plasminogen activator inhibitor type 1 in the inflammatory response to local tissue injury. J Thromb Haemost 2005;3:1018-25.
69. Fain JN, Madan AK. Insulin enhances vascular endothelial growth factor, interleukin-8, and plasminogen activator inhibitor-1 but not interleukin-6 release by human adipocytes. Metabolism 2005;54:220-6.
70. He G, Bruun JM, Lihn AS, Pedersen SB, Richelsen B. Stimulation of PAI-1 and adipokines by glucose in human adipose tissue in vitro. Biochem Biophys Res Commun 2003;310:878-83.
71. Pandey M, Loskutoff DJ, Samad F. Molecular mechanisms of tumor necrosis factor-alpha-mediated plasminogen activator inhibitor-1 expression in adipocytes. FASEB J 2005 (Epub ahead of print).
72. Skurk T, Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Relat Metab Disord 2004;28:1357-64.
73. Umpaichitra V, Hussain MM, Castells S. Plasminogen activator inhibitor-1 and tissue-plasminogen activator in minority adolescents with type 2 diabetes and obesity. Pediatr Res 2005 May (Epub ahead of print).
74. Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress and lipid peroxidation in patients with hyperglycemic crises. Diabetes 2004;5:2079-86.
75. Kinik ST, Atac FB, Verdi H, Cetintas S, Sahin FI, Obzbek N. The effect of plasminogen activator inhibitor-1 gene4G/5G polymorphism on glucose and lipid metabolism in Turkish obese children. Clin Endocrinol (Oxf) 2005;62:607-10.
76. Grant PJ. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 2003;29(4Pt2):6S44-52.
77. Ma LJ, Mao SL, Taylor KL, Kanjanabuch T, Guan Y, Zhang Y, et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004;53:336-46.
78. Dhinsda G, Bhatia R, Dhindsda M, Bhatia V. Insulin resistance, insulin sensitization and inflammation in polycystic ovarian syndrome. J Postgrad Med 2004;50:140-4.
79. Sobel BE, Taatjes DJ, Schneider DJ. Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis. Arteriosclerosis Thromb Vasc Biol 2003;23:1979-96.
80. Sakata T, Mannami T, Baba S, Kokubo Y, Kario K, Okamoto A, et al. Potential of free-form TFPI and PAI-1 to be useful markers of early atherosclerosis in a Japanese general population (the Suita Study): association with the intimal-medial thickness of carotid arteries. Atherosclerosis 2004;176:355-60.
81. Gyongyosi M, Glogar D, Weidinger F, Domanovits H, Laggner A, Wojta J, et al. Association between plasmin activation system and intravascular ultrasound signs of plaque instability in patients with unstable angina and non-st-segment elevation myocardial infarction. Am Heart J 2004;147:158-64.
82. Nielsen NE, Logander E, Swahn E. Fibrinolytic variables in postmenopausal women with unstable coronary artery disease. J Thromb Thrombolysis 2001;12:217-23.
83. Sinkovic A, Pogacar V. Risk stratification in patients with unstable angina and/or non-ST-elevation myocardial infarction by Troponin T and plasminogen-activator-inhibitor-1 (PAI-1). Thromb Res 2004;114:251-7.
84. Collet JP, Montalescot G, Vicaut E, Ankri A, Waylo F, Lesty C, et al. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation. 2003;108:391-4.
85. Lindgren A, Lindhoff C, Norrving B, Astedt B, Johansson BB. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients. Stroke 1996;27:1066-71.
86. Catto AJ, Carter AM, Stickland M, Bamford JM, Davies JA, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thromb Haemost 1997;77:730-4.
87. Swiatkiewicz A, Jurkowski P, Kotschy M, Ciecierski M, Jawien A. Level of antithrombin III, protein C, protein S and other selected parameters of coagulation and fibrinolysis in the blood of the patients with recurrent deep vein thrombosis. Med Sci Monit 2002;8:CR263-8.
88. Schulman S, Wilman B. The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Duration of anticoagulation (DURAC) Trial Study group. Thromb Haemost 1996;75:607-11.
89. Iijima H, Iida T, Murayama K, Imai M, Gohdo T. Plasminogen activator inhibitor 1 in central serous chorioretinopathy. Am J Ophthalmol 1999;127:477-8.
90. Salat C, Holler E, Kolb HJ, Reinhardt B, Pihusch R, Wilmanns W, et al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood 1997;89:2184-8.
91. Pihusch V, Pihusch M, Penovici M, Kolb HJ, Hiller E, Pihusch R. Transforming growth factor beta-1 released from platelets contributes to hypercoagulability in veno-occlusive disease following hematopoetic stem cell transplantation. Thromb Res 2005;116:233-40.
92. Pihusch M, Wegner H, Goehring P, Salat C, Hiller E, Andreesen R, et al. Diagnosis of hepatic veno-occlusive disease by plasminogen activator inhibitor-1 plasma antigen levels: a prospective analysis in 350 allogeneic hematopoietic stem cell recipients. Transplantation 2005, in press.
93. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JP. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 1997;95:59-62.
94. Zhan M, Zhou Y, Han Z. Plasminogen activator inhibitor-1 4G/5G gene polymorphism in patients with myocardial or cerebrovascular infarction in Tianjin, China. Chin Med J (Engl) 2003;116:1707-10.
95. Pihusch M, Lohse P, Reitberger J, Hiller E, Andreesen R, Kolb HJ, et al. Impact of thrombophilic gene mutations and graft-versus-host disease on thromboembolic complications after allogeneic hematopoietic stem-cell transplantation. Transplantation 2004;78:911-8.
96. Sartori MT, Danesin C, Saggiorato G, Tormene D, Simioni P Spieza L, et al. The PAI-1 gene 4G/5G polymorphism and deep vein thrombosis in patients with inherited thrombophilia. Clin Appl Thromb Hemost 2003;9:299-307.
97. Boekholdt SM, Bijsterveld NR, Moons AH, Levi M, Büller HR, Peters RJ. Genetic variations in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction. Circulation 2001;104:3063-74.
98. Lane DA, Grand PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000;95:1517-32.